Changing the future of Oncology.

Leadership Team

Edward Albini, M.B.A

Chief Financial Officer

Edward Albini has served as our Chief Financial Officer since January 2013. During 2012, Mr. Albini served as a consulting Chief Financial Officer for Carbylan Biosurgery, a company focused on the development and commercialization of advanced biomaterial-based joint therapies. From 2011 to 2016, Mr. Albini also served as Chief Financial Officer and Secretary for Itero Holdings, LLC, a successor entity to Itero Biopharmaceuticals, Inc., a company focused on the development and commercialization of protein therapeutics, at which Mr. Albini served as Chief Financial Officer and Senior Vice President from 2009 to 2011. Previously, Mr. Albini served as Chief Financial Officer of Novacea, Inc. and Lynx Therapeutics, Inc., both biopharmaceutical companies. Mr. Albini received a B.S.C. in Accounting from Santa Clara University and an M.B.A. from the Walter A. Haas School of Business at the University of California, Berkeley. Mr. Albini is also a certified public accountant (inactive status) in California.

Shabbir Anik, Ph.D.

Chief Technical Operations Officer

Shabbir T. Anik, Ph.D., has served as our Chief Technical Operations Officer since March 2016. From August 2011 to December 2015, Dr. Anik served as Senior Vice President of Technical Operations at Onyx Pharmaceuticals, Inc., a pharmaceutical company focused on developing medicines for the treatment of cancer. Previously, Dr. Anik served as President and Chief Executive Officer of Althea Technologies Inc., President of Global Pharmaceutical Development Services and Chief Scientific Officer for Patheon Inc. and in various leadership positions at Neurex Corporation and Syntex Inc. Dr. Anik received a B.S. in Pharmacy from the University of Bombay, a Ph.D. in Pharmaceutical Sciences from the University of Wisconsin, Madison and an M.B.A. from Santa Clara University.

Kristin Bedard, Ph.D.

VP Discovery

Dr. Bedard previously held leadership positions at Kineta, most recently as Chief Scientific Officer, Immuno-oncology and Senior Vice President, Discovery and formerly as Vice President of R&D and Head of Virology. She is the co-inventor of fifteen filed U.S. patent applications for novel classes of antivirals, adjuvants, immune agonists and their corresponding methods of identification. Dr. Bedard received her B.S. from Pennsylvania State University and earned her Ph.D. from University of California, Irvine.  

Craig Berman, M.D.

VP Clinical

Craig Berman, M.D. has over 17 years of experience in drug development and held increasing leadership positions. Most recently, as a Vice President of Clinical Development at QED Therapeutics. Dr. Berman lead the clinical development of PEGPH20 at Halozyme from 2016-2018, cabozantinib at Exelixis 2013-2015, and enzalutamide at Medivation (currently Pfizer) 2009-2013, including successful NDA and launch. Dr. Berman has worked on several immune oncology programs including, GVAX whole cell vaccine at Cell Genesys, intratumoral injection of TLR-9 agonists in combination with pembrolizumab at Dynavax, and PEGPH20 in combination with atezolizumab in collaboration with Genentech and Halozyme. Dr. Berman received a B.A. in Chemistry from Northwestern University in Evanston, an M.D. from the University of Colorado Health Sciences Center and completed a residency in urology at the University of Iowa and post-residency training in urologic oncology at the University of Colorado. 

Regina Cheng

VP Finance and Controller

Regina Cheng has 25 years of financial accounting experience and has managed our finance and accounting team since 2015. Prior to joining Sutro, while at Keynote Systems (acquired by Thoma Bravo, LLC), she built and led the finance team as the company’s first controller and assisted in its highly successful initial public offering and follow-on financing. Ms. Cheng has also held various corporate and divisional controllership management positions at several private and publicly held technology companies, such as CompareNetworks, Inc., TeraRecon (acquired by SymphonyAI Group), Sungard Data Systems (acquired by FIS) and Sterling Software (acquired by Computer Associates). Ms. Cheng received her B.A. from the University of California, Berkeley, and is a certified public accountant (inactive status) in California.

Nicole M. Chieffo, M.B.A.

VP Clinical Operations

Nicole Chieffo has over 25 years of clinical operations and development experience. Nicole joins Sutro from Janssen Pharmaceuticals where she previously held Sr. Director, Oncology Global Operations Head and Lead Oncology Clinical Scientist positions.  Nicole worked directly with Janssen’s medical oncology and hematology physician team leaders in advancing the Early and Late-Stage Research and Development portfolio.  In this capacity, Nicole led and supported clinical operations at Janssen, resulting in successful approvals of ZYTIGA®, SYLVANT®, YONDELIS®, IMBRUVICA®, DARZALEX®, ERLEADA®, BALVERSA™, and RYBREVANT™. Prior to Janssen, Nicole was with Cougar Biotechnology Inc. (acquired by Janssen in 2009) and established the Clinical Operational infrastructure to manage the development of Abiraterone Acetate (Zytiga). Nicole held various operational positions at IDEC Pharmaceuticals, a predecessor of Biogen Idec, and led the Global Clinical Development Teams for multiple indications (Non-Hodgkin’s and Hodgkin’s Lymphoma, multiple solid tumors, and psoriasis) of target monoclonal antibodies.  Nicole has also held various clinical operations and development positions at Dura and Amylin Pharmaceuticals, Immune Response Corporation, and Oncology Pre-Clinical Research positions at University of Pennsylvania, Department of Radiation Oncology, and Adamantech Inc. Nicole holds degrees in Animal Science, a B.A. in Business Management, and a Master’s in Business Administration (MBA).

Jane Chung, RPh

Chief Commercial Officer 

Jane Chung, RPh has over 20 years of pharmaceutical and biotechnology experience building and leading commercial teams.  Ms. Chung joins Sutro from AstraZeneca where she most recently served as President and General Manager of AstraZeneca Canada since 2019; and Vice President and Head of U.S. Immuno-Oncology franchise from 2017 to 2019; and Senior Commercial Business Director from 2015 to 2017.  Previously, Ms. Chung served as Oncology Region Sales Director and Hematology Director at Onyx Pharmaceuticals from 2013 to 2015 and held diverse roles in Commercial Operations, Marketing and Sales at Genentech from 2003 to 2013.  Ms. Chung received her B.A. from Columbia University, New York, and B.S. in Pharmacy from St. John’s University, New York.

Linda Fitzpatrick

Chief People and Communications Officer 

Linda Fitzpatrick has served as our Chief People and Communications Officer since August 2018. From January 2008 to August 2018, Ms. Fitzpatrick served as our VP of Human Resources and Communications in the capacity of Senior Advisor. In addition to her strategic consulting practice, she co-founded Parallax Venture Partners, an early stage health care venture fund in April 2002. From October 1992 to March 2002, Ms. Fitzpatrick served as Vice President of Human Resources, Corporate Communications and Operations for Gilead Sciences, Inc. and from February 1985 to September 1992 she served as Director of Investor Relations and Director of Compensation, Benefits and Systems for Genentech, Inc., in addition to heading the human resources and corporate communications strategy for a variety of publicly held biotechnology companies. Ms. Fitzpatrick also serves on a variety of non-profit boards, including board chair roles, in the science, education and community development arenas. Ms. Fitzpatrick received a B.A. in Psychology and Sociology from San Francisco State University.

Trevor Hallam, Ph.D.

President of Research and Chief Scientific Officer

Trevor J. Hallam, Ph.D., has served as our Chief Scientific Officer since December 2010. Prior to joining us, Dr. Hallam was Executive Vice President of Research & Development at Palatin Technologies, Inc., and held several senior management positions in various pharmaceutical companies, including AstraZeneca PLC, SmithKline & French Laboratories, Ltd., Glaxo Group Research Ltd., Roche Research and Rhone-Poulenc Rorer. Dr. Hallam received a BSc (Hons) in Biochemistry from the University of Leeds and a Ph.D. in Biochemistry from Kings College, University of London. He then conducted post-doctoral training at the Physiological Laboratory, University of Cambridge.

Diana Landa, M.S.

VP Regulatory Affairs

Diana Landa joins Sutro from Amgen where she recently held an Executive Director, Global Regulatory Affairs position. Ms. Landa provided leadership for the development and execution of global regulatory strategies for the biosimilar portfolio in the oncology and inflammation therapeutic areas. While at Amgen, Ms. Landa led numerous Health Authority interactions and marketing applications with FDA, EMA, PMDA, Health Canada and ROW. Prior to Amgen, Ms. Landa was with Teva Pharmaceuticals where she led the global regulatory filings for innovative programs in the hematology therapeutic area with leadership of cross-functional teams from IND to BLA stage.

Ms. Landa brings 20 years of Global Regulatory Affairs experience with new product development and marketed product life-cycle management with expertise in biologics and small molecules.  She brings extensive experience in leading global Health Authority interactions, negotiating strategies with respect to CMC and clinical development and a successful track record of marketing applications world-wide. 

Ms. Landa received her M.S. in Regulatory Affairs/ Quality Assurance from Temple University School of Pharmacy and her B.A.  in Chemistry and Biochemistry from LaSalle University.

Carlos Lugo

VP Quality and CMC Regulatory Operations

Carlos Lugo has over 25 years of combined experience in quality, compliance regulatory affairs, validation and manufacturing, and has been the Head of Quality for Sutro since 2016. Prior to joining Sutro, Carlos held the role of Global Quality Systems Director at Bayer supporting KogenateTM and KovaltryTM hematology products. Similarly, as QA Director, he was directly involved in the early phase clinical supply activities leading to the successful commercial launch of Keytruda® at Merck & Co.  Carlos has also held various increased leadership positions at Hospira (acquired by Pfizer), Johnson & Johnson, Bristol-Myers Squibb and Baxter supporting large molecules, small molecules, medical devices and combination products. Mr. Lugo received his B.S. in Chemical Engineering from the University of Puerto Rico, Mayagüez Campus.

Devendra Luhar

VP Manufacturing and Plant Operations

Mr. Luhar has over 30 years of experience in biotech operations, including Manufacturing, Manufacturing Science and Technology, Engineering and Logistics. He joined Sutro in 2016 as Senior Director of Manufacturing and was promoted to Executive Director in 2018. At Sutro, Mr. Luhar has led the formation of Sutro’s manufacturing organization and GMP compliant operations and is responsible for Sutro’s cGMP manufacturing facility. Prior to joining Sutro, Mr. Luhar held senior leadership positions at Boehringer-Ingelheim, Novartis, Genzyme, and Baxter Bioscience where he worked for 12 years. Mr. Luhar received his B.A. in Biology from San Jose State University.

Andreas Maderna, Ph.D.

VP Chemistry

Dr. Maderna joins the Sutro team after spending the majority of his career at Pfizer in the department of oncology medicinal chemistry. As an associate research fellow, he led multiple chemistry design teams in hit to lead optimization campaigns of small molecule programs directed at various immuno-oncology, cell singling and epigenetic targets. Dr. Maderna’s expertise also includes antibody drug conjugates (ADC’s). At Pfizer, he led the payload discovery and development efforts to support Pfizer’s antibody drug conjugate portfolio. His team developed new and highly potent payloads that led to multiple ADC clinical candidates. For his contributions Dr. Maderna received the 2015 Pfizer Worldwide Research and Development Individual Achievement Award. Before joining Pfizer Dr. Maderna was the project leader of multiple oral kinase inhibitor projects at Wyeth and Valeant Pharmaceuticals. He discovered the MEK inhibitor Refametinib which has been investigated in multiple phase 1 and phase 2 studies. Dr. Maderna obtained his Ph.D. in Chemistry at the University of Heidelberg, Germany. He is the author of over thirty publications and presentations and is the co-inventor on over fifteen patents and patent applications.

Arturo Molina, M.D., M.S., FACP

Chief Medical Officer

Arturo Molina, M.D., M.S., FACP, has served as our Chief Medical Officer since February 2016. From February 2013 to February 2016, Dr. Molina served as Vice President of Oncology Scientific Innovation at Johnson & Johnson’s California Innovation Center, an organization focused on building early stage collaborations with emerging companies. Previously, Dr. Molina served as Chief Medical Officer and Vice President of Clinical Development for Johnson and Johnson’s Ortho Biotech Oncology Research and Development, a unit of Cougar Biotechnology, Inc., Chief Medical Officer of Cougar Biotechnology, Inc., Senior Director and Interim Head of Oncology/Hematology in the Department of Medical Research and Clinical Development at Biogen Idec, Inc., and Senior Director of Medical Affairs at IDEC Pharmaceuticals Corporation. Since 2006, Dr. Molina has served as a National Advisory Committee Member for the Harold Amos Medical Faculty Development Program of the Robert Wood Johnson Foundation. From 1991 to 2002, Dr. Molina was a faculty staff physician in the Department of Hematology/Bone Marrow Transplantation and Department of Medical Oncology/Therapeutics Research at City of Hope Comprehensive Cancer Center and Adjunct Professor from 2004 to 2007. Dr. Molina was also on the Board of Directors of the City of Hope Medical Group. Dr. Molina received a B.S. in Zoology and B.A. in Psychology from the University of Texas at Austin and an M.S. in Physiology and M.D. from Stanford University School of Medicine. He is board certified in internal medicine and medical oncology, has an active California medical license and is a staff physician (volunteer) in the Oncology Clinic at the Veterans Affairs Palo Alto Health Care System. Since January 2019, Dr. Molina has been an Adjunct Clinical Associate Professor (volunteer) in the Department of Medicine, Division of Oncology, Stanford University School of Medicine.

William J. Newell 

Chief Executive Officer

William J. Newell has served as our Chief Executive Officer and a member of our Board of Directors since January 2009. Previously, he served as the President of Aerovance, Inc., a biotechnology company focused on respiratory diseases, from 2006 to 2007. Mr. Newell has also served as the Chief Business Officer and Senior Vice President at QLT Inc., in several senior management positions at Axys Pharmaceuticals, Inc., and has experience as a corporate lawyer. He currently serves on the boards of directors of  Biotechnology Innovation Organization’s Health Section and Emerging Company Section and the California Life Sciences Association, where he also serves as a member of the executive committee. Mr. Newell received an A.B. in Government from Dartmouth College and a J.D. from the University of Michigan Law School. We believe that Mr. Newell is qualified to serve on our Board of Directors because of his experience with various biotechnology companies, including working with and serving in various executive positions in life sciences companies.

David Pauling, J.D., M.A.

General Counsel

Mr. Pauling joined Sutro in 2011 and has since held positions of increasing responsibility, including Intellectual Property Counsel, Associate General and Senior Intellectual Property Counsel, and most recently Executive Director of Legal Affairs. Prior to joining Sutro, Mr. Pauling practiced law at Jones Day and at Penne & Edmonds, LLP. Mr. Pauling received his J.D. from Santa Clara University School of Law (magna cum laude), and an M.A. in Molecular Biology and a B.S. in Biochemistry and Molecular Biology from the University of California, Santa Cruz.

Werner Rubas, Ph.D.

VP Preclinical Development

Werner Rubas, Ph.D., brings to Sutro 30 years of biotech and pharmaceutical industry experience. Formerly, Dr. Rubas was at Nektar Therapeutics for over nine years, most recently as Executive Director in Non-Clinical Pharmacokinetics and Pharmacodynamics. At Nektar he provided leadership support, directed the generation of data packages for regulatory submissions of NKTR-214, NKTR-358, NKTR-262 and NKTR-255, filed a patent application for an immunotherapeutic tumor treatment method, and provided scientific input on cross-functional teams from research concepts to late stage development. Prior to Nektar, Dr. Werner was at Roche in Palo Alto, where he was the Associate Director of the Drug Metabolism and Pharmacokinetics group. Additionally, he has been a SPARK advisor at Stanford University since 2010 and lectures classes on Drug Development at UC Berkeley Extension. Dr. Rubas earned his Ph.D. from ETH, Zurich and received his pharmacy license from the School of Pharmacy at ETH, Zurich.

Brunilda Shtylla, M.B.A

VP Business Development

Ms. Shtylla worked as an independent consultant since 2012, which included consulting for Genentech since 2013. Prior to this, she held numerous positions at Lifescan, a Johnson & Johnson company, including Associate Director of Partnerships and Product Director, U.S. Brand Marketing. Previously, Ms. Shtylla held roles in Business Development, Technology Transfer, Sales & Operations Planning, Investment Banking and Finance. She received her B.S. from Wayne State University, a M.S. in Mathematics from Youngstown State University and an M.B.A. from Stanford Graduate School of Business. 

Nicki Vasquez, Ph.D.

Chief Portfolio Strategy & Alliance Officer 

Dr. Vasquez has 25 years of biopharmaceutical discovery research and development experience and has lead our alliance and portfolio management since 2015.  Prior to joining Sutro, she was Vice President of Program & Portfolio Management at StemCells, Inc., where she was responsible for establishing project management of research and clinical stage programs exploring HuCNS-SC stem cell therapy for Alzheimer’s Disease, spinal cord injury and dry AMD. Prior to that she was at Elan, where she held positions of increasing responsibility from Alzheimer’s Disease and autoimmune discovery research, to Vice President Research Operations & Program Management, and Vice President Development Program & Portfolio Management.  Dr. Vasquez obtained her doctoral degree in immunology from the University of California, San Diego, and received her post-doctoral training at Genentech.